	US 11,944,645 B2
	Modified cell and use thereof in gene and cell therapy
Zhiyuan Cao, Shanghai (CN); Lei Xiao, Rockville, MD (US); Yuzhe Peng, Shanghai (CN); Wei Ding, Shanghai (CN); and Wensheng Wang, Shanghai (CN)
Assigned to Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY); and Innovative Cellular Therapeutics, Inc., Rockville, MD (US)
Filed by Innovative Cellular Therapeutics Holdings, Ltd., Grand Cayman (KY); and Innovative Cellular Therapeutics, Inc., Rockville, MD (US)
Filed on Sep. 30, 2021, as Appl. No. 17/490,582.
Claims priority of provisional application 63/086,343, filed on Oct. 1, 2020.
Prior Publication US 2022/0105134 A1, Apr. 7, 2022
Int. Cl. A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01)

CPC A61K 35/17 (2013.01) [C07K 14/4702 (2013.01); C07K 14/7051 (2013.01)]

20 Claims

1. A method of enhancing an anti-tumor effect of a lymphocyte, the method comprising:

introducing an exogenous polynucleotide encoding Caveolae Associated Protein 3 (CAVIN3) or Zinc finger bed-type containing 2 (ZBED2) into lymphocytes to obtain modified lymphocytes;

contacting the modified lymphocytes with tumor cells that the modified lymphocytes bind; and

allowing the modified lymphocytes to generate an anti-tumor effect, wherein the anti-tumor effect of the modified lymphocytes is enhanced as compared to lymphocytes that do not express an exogenous CAVIN3 and ZBED2.